Studies with aprindine.
Aprindine is a very effective antiarrhythmic agent with a narrow therapeutic-toxic ratio. It has been used successfully in treating patients who have both supraventricular and ventricular tachyarrhythmias. Aprindine slows conduction in all cardiac fibers and suppresses digitalis-induced after-depolarizations. Voltage-clamp studies indicate that aprindine, in higher doses, suppresses the slow inward current in frog atria. In the dog subjected to coronary artery occlusion, aprindine may be arrhythmogenic, antiarrhythmic, or have no effect on the development of arrhythmias, depending on the temporal relationship between time of administration and time of occlusion.
D000380:Agranulocytosis / Q000139:chemically induced; D000818:Animals; D001073:Aprindine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D002779:Cholestasis / Q000139:chemically induced; D004285:Dogs; D004594:Electrophysiology; D006801:Humans; D007192:Indenes / Q000627:therapeutic use*; D007473:Ion Channels / Q000187:drug effects; D011895:Rana ridibunda; D012008:Recurrence; D013610:Tachycardia / Q000188:drug therapy; D014693:Ventricular Fibrillation / Q000188:drug therapy
D007192:Indenes; D007473:Ion Channels; D001073:Aprindine